D-Nome raises $1.5 million in funding from Ankur Capital, Campus Fund
D-Nome, a business in synthetic biology, received $1.5 million in seed money from Ankur Capital, Campus Fund, and additional investors. D-deviceless Nome's PCR technology aims to democratise molecular diagnostics.
The startup, founded in July 2021 by scientists Divya Sriram and Sujoy Deb from Telangana's Atal Incubation Centre-The Centre of Cellular and Molecular Biology, focuses on developing quick point-of-care diagnostics for infectious diseases affecting humans as well as other applications using genomics and synthetic biology.
“Our mission is to fill the gap in testing and enable personalised medicine at scale, something that has not been successful due to the lack of scalable and accurate diagnostic tools. We hope to create significant impact socially and economically for developing nations and pave the way for next-generation healthcare relying heavily on genomics,”
There are currently three primary testing methods: routine culture, which takes time and infrastructure to perform, rapid antigen/antibody tests, which are quicker but less accurate, and PCR/ Real time PCR (RT-PCR) tests, which are the gold standard for accuracy but are pricy and require skilled labour.
The startup, founded in July 2021 by scientists Divya Sriram and Sujoy Deb from Telangana's Atal Incubation Centre-The Centre of Cellular and Molecular Biology, focuses on developing quick point-of-care diagnostics for infectious diseases affecting humans as well as other applications using genomics and synthetic biology.
“Our mission is to fill the gap in testing and enable personalised medicine at scale, something that has not been successful due to the lack of scalable and accurate diagnostic tools. We hope to create significant impact socially and economically for developing nations and pave the way for next-generation healthcare relying heavily on genomics,”
There are currently three primary testing methods: routine culture, which takes time and infrastructure to perform, rapid antigen/antibody tests, which are quicker but less accurate, and PCR/ Real time PCR (RT-PCR) tests, which are the gold standard for accuracy but are pricy and require skilled labour.
